Grifols (GIKLY) Return on Capital Employed (2011 - 2020)
Grifols (GIKLY) reported Return on Capital Employed of 46.95% for Q1 2020, up 3.25% quarter-over-quarter from 45.47% in Q4 2019.
Grifols (GIKLY) Return on Capital Employed (2011 - 2020) Analysis & Trends
Grifols has reported Return on Capital Employed for 9 years, with the latest figure at 46.95% in Q1 2020.
- For the quarter ending Q1 2020, Return on Capital Employed changed N/A year-over-year to 46.95%; the trailing twelve-month figure through Mar 2020 stood at 46.95% (changed N/A YoY), and the FY2025 full-year result was 15.79%, down 163834.0% from the prior year.
- Return on Capital Employed for Q1 2020 stood at 46.95%, up from 45.47% in the prior quarter.
- The five-year high for Return on Capital Employed was 48.91% in Q4 2018, with the low at 5.29% in Q4 2016.
- Historically, Return on Capital Employed has averaged 27.18% across 5 years, with a median of 27.69% in 2018.
- Annual changes were most pronounced in 2016 — Return on Capital Employed slumped 2252 bps — and 2018, when it soared 2955 bps.
- Grifols' Return on Capital Employed stood at 5.29% in 2016, then jumped by 466 bps to 19.35% in 2017, then jumped by 153 bps to 48.91% in 2018, then retreated by 7 bps to 45.47% in 2019, then increased by 3 bps to 46.95% in 2020.
- The last three Return on Capital Employed figures came in at 46.95% (Q1 2020), 45.47% (Q4 2019), and 48.91% (Q4 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -6.84% |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 46.95% |
| Dec 31, 2019 | 45.47% |
| Dec 31, 2018 | 48.91% |
| Jun 30, 2018 | 27.69% |
| Mar 31, 2018 | 28.78% |
| Dec 31, 2017 | 19.35% |
| Dec 31, 2016 | -5.29% |
| Sep 30, 2016 | 16.09% |
| Jun 30, 2016 | 16.70% |
| Dec 31, 2015 | 17.24% |
| Mar 31, 2015 | 10.72% |
| Sep 30, 2013 | 39.77% |
| Jun 30, 2013 | 39.67% |
| Mar 31, 2013 | 39.16% |
| Dec 31, 2012 | 39.59% |
| Sep 30, 2012 | 16.92% |
| Jun 30, 2012 | 16.34% |
| Mar 31, 2012 | 19.98% |
| Dec 31, 2011 | 19.72% |
| Sep 30, 2011 | 19.04% |